News & Publications
Gate Neurosciences, a clinical-stage biotechnology company using precision medicine approaches to develop next-generation neuroscience therapies, today announced its upcoming activities at the annual meeting of the American Society of Clinical Psychopharmacology (ASCP), being held in Miami Beach, FL, from May 30-June 2, 2023.
Expanded research operations led by Drs. Joseph Moskal and Jeffery Burgdorf of Northwestern University, pioneers of the “stinel” class of NMDA receptor modulators. Research focused on advancing translational qEEG biomarkers, dosing, and mechanism insights underlying Gate’s synaptic function enhancing molecules. Key insights further support a next confirmatory Phase 2 study of lead oral program zelquistinel in major depressive disorder.
“Gate Neurosciences’ CSO, Dr. Anantha Shekhar, gave a lecture at the Indiana University the class of NMDA receptor modulators that zelquistinel and apimostinel belong to. His lecture covers the class’ history, its mechanism and differences versus NMDA antagonists (e.g. ketamine) — along with what clinical trials have shown thus far.”
Ketamine is a well-characterized NMDA receptor (NMDAR) antagonist, although the relevance of this pharmacology to its rapid (within hours of administration) antidepressant actions, which depend on mechanisms convergent with strengthening of excitatory synapses, is unclear. Activation of synaptic NMDARs is necessary for the induction of canonical long-term potentiation (LTP) leading to a sustained expression of increased synaptic strength.
Gate Neurosciences was featured in Psychiatric Times’ mental health minute video series. Co-founder of Gate Neurosciences and Senior Vice Chancellor for Health Sciences and Dean of the University of Pittsburgh School of Medicine, Dr. Shekhar, discusses apimostinel, a safe and rapid-acting injectable being developed for acute depression, and Gate Neuro’s ongoing EEG biomarker study.
Gate Neurosciences today announced that the first cohort of subjects has been dosed in its Phase 1 biomarker and multiple ascending dose study of apimostinel, the company’s 2nd generation rapid-acting injectable NMDAR modulator program.
Gate Neurosciences today announced the results of research, published in the International Journal of Neuropsychopharmacology, supporting the mechanism of action and clinical foundation of Zelquistinel – the company’s lead oral program in Phase 2 development – as a rapid-acting, long-lasting and safe antidepressant.
Gate Neurosciences today announced it has officially launched to develop its next-generation therapeutics addressing synaptic dysfunction in patients suffering from central nervous system (CNS) disorders.
Highlights our lead program, Zelquistinel, and it’s unique mechanism of positive NMDA receptor modulation and that enhances long-term potentiation and synaptic function, resulting in rapid and sustained antidepressant activity with an improved safety profile versus NMDA antagonists.
Highlights the differentiated mechanism and effects on cognition of our class of NMDAR modulators, compared to NMDAR antagonists. Gate’s unique NMDAR modulator mechanism reverses and rescues brain deficits caused by NMDAR antagonists such as PCP and ketamine.